B. Riley reissued their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research note published on Tuesday morning. They currently have a $206.00 price objective on the specialty pharmaceutical company’s stock.

A number of other research firms have also recently commented on JAZZ. Zacks Investment Research upgraded Jazz Pharmaceuticals from a hold rating to a buy rating and set a $174.00 price objective for the company in a research report on Tuesday, August 8th. Deutsche Bank set a $175.00 price target on Jazz Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, August 9th. Royal Bank Of Canada reiterated a buy rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 9th. Janney Montgomery Scott reiterated a buy rating and set a $192.00 price target (up from $180.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 9th. Finally, J P Morgan Chase & Co reiterated a buy rating and set a $190.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday, September 18th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and nineteen have given a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $181.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ) traded down $0.81 during trading on Tuesday, hitting $135.75. The stock had a trading volume of 451,300 shares, compared to its average volume of 508,983. The stock has a market capitalization of $8,186.84, a PE ratio of 17.13, a PEG ratio of 0.88 and a beta of 0.98. Jazz Pharmaceuticals has a 1-year low of $99.28 and a 1-year high of $163.75. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.10 and a quick ratio of 2.94.

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $153.52, for a total value of $153,520.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Iain Mcgill sold 8,000 shares of the company’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $133.42, for a total value of $1,067,360.00. Following the completion of the sale, the senior vice president now owns 28,383 shares of the company’s stock, valued at $3,786,859.86. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,352 shares of company stock valued at $1,417,763. 4.30% of the stock is owned by company insiders.

Large investors have recently modified their holdings of the business. Toronto Dominion Bank lifted its stake in shares of Jazz Pharmaceuticals by 12.4% in the 2nd quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after purchasing an additional 81 shares during the last quarter. US Bancorp DE lifted its stake in shares of Jazz Pharmaceuticals by 94.4% in the 2nd quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 368 shares during the last quarter. Gargoyle Investment Advisor L.L.C. acquired a new position in shares of Jazz Pharmaceuticals in the 2nd quarter valued at $206,000. Advisor Group Inc. lifted its stake in shares of Jazz Pharmaceuticals by 62.4% in the 3rd quarter. Advisor Group Inc. now owns 1,431 shares of the specialty pharmaceutical company’s stock valued at $210,000 after purchasing an additional 550 shares during the last quarter. Finally, Janney Montgomery Scott LLC acquired a new position in shares of Jazz Pharmaceuticals in the 2nd quarter valued at $211,000. Institutional investors own 91.30% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/jazz-pharmaceuticals-jazz-receives-buy-rating-from-b-riley/1747876.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.